L&C Bio Signed U.S. Supply Agreement
The biotech firm finalized a $60 million deal to distribute its tissue products in the American market.
Updated on Oct. 12, 2026 in Biotech
Live Poll
Do you trust that new medical supply partnerships will increase access to quality healthcare in your area?
L&C Bio has entered an exclusive supply agreement with a U.S. distributor to provide its Re2O product. The contract is valued at a minimum of $60 million and utilizes the FDA Section 361 regulatory framework for human cell and tissue products.
Why it matters
This partnership enables L&C Bio to leverage a network of approximately 17,000 medical clients across the United States. The agreement marks a significant step in the company's international expansion and production strategy.
The agreement covers a minimum purchase quantity of 150mg of Re2O. The current terms explicitly exclude the company's Re2O Fine and Re2O V product lines from the initial supply contract.
The players
L&C Bio
L&C Bio is a biotechnology company that specializes in the development and manufacturing of regenerative medical products.
The details
L&C Bio is preparing for future supply requirements by upgrading existing facilities and constructing a new plant in Dongtan. The company intends to educate medical professionals on the product throughout the remainder of 2026 before launching formal supply operations.
Timeline
L&C Bio will conduct product education for medical professionals through the remainder of 2026.
Product supply to the United States market is scheduled to begin in 2027.
The Tech Race
This deal underscores the aggressive expansion of international biotech firms into the competitive U.S. regenerative medicine sector. By securing established distribution networks, foreign entities are rapidly scaling their footprint against domestic incumbents.
Medical professionals and patients in the United States may gain access to new regenerative treatment options beginning in 2027. The agreement ensures that the distributed products meet the specific compliance standards required by the FDA.
The takeaway
L&C Bio continues to scale its global production capacity to meet the demands of international expansion. Healthcare providers should monitor for updates on product availability as the company ramps up its U.S. supply chain operations.
Further reading
For more information on industry trends, see our Biotech section.
Source note: This article includes information reported by 조선일보.
Live Poll
Do you trust that new medical supply partnerships will increase access to quality healthcare in your area?
